In the current study, focusing on AML patients with WT1 mutation undergoing transplantation from MSD, UD, or haploidentical donors, while in CR1, we assessed the impact of mWT1 on HSCT outcomes in comparison to transplantation outcomes of AML patients with wtWT1. Here, WT1 is linked to acute myeloid leukemia.